读医学网

Approximately 50% of patients with systemic lupus erythematosus (SLE) will develop lupus nephritis (LN), which increases the risks for renal failure, cardiovascular disease and death. In 2008, we published the first European League Against Rheumatism (EULAR) recommendations on the management of SLE.1 Since then, several controlled trials have been published upon which updated recommendations can be based. The realisation that in the care of patients with LN internists/rheumatologists and nephrologists are involved, prompted us to develop recommendations for LN under the joint auspices of the EULAR and the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA), with experts from both disciplines. The panel was enriched with renal pathologists and paediatricians with expertise on LN.